Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Rev Vaccines. 2014 Mar;13(3):345-64. doi: 10.1586/14760584.2014.880341. Epub 2014 Jan 29.

Neisseria meningitidis B vaccines: recent advances and possible immunization policies.

Author information

1
Department of Health Sciences, University of Genoa, Genoa, Italy.

Abstract

Since the development of the first-generation vaccines based on outer membrane vesicles (OMV), which were able to contain strain-specific epidemics, but were not suitable for universal use, enormous steps forward in the prevention of Neisseria meningitidis B have been made. The first multicomponent vaccine, Bexsero(®), has recently been authorized for use; other vaccines, bivalent rLP2086 and next-generation OMV vaccines, are under development. The new vaccines may substantially contribute to reducing invasive bacterial infections as they could cover most Neisseria meningitidis B strains. Moreover, other potentially effective serogroup B vaccine candidates are being studied in preclinical settings. It is therefore appropriate to review what has recently been achieved in the prevention of disease caused by serogroup B.

PMID:
24476428
DOI:
10.1586/14760584.2014.880341
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center